Raphael Pharmaceutical Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Comprehensive Loss
| Nine months ended September 30, | Three months ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Unaudited · Unaudited | ||||
| Research and development expenses | $565 | $917 | $162 | $510 |
| General and administrative expenses | 550 | 489 | 157 | 219 |
| Operating loss | 1,115 | 1,406 | 319 | 729 |
| Total financial expense (income), net | 9 | (*) | 7 | (4) |
| Net loss | 1,124 | 1,406 | 326 | 725 |
| Basic and diluted net loss per share | 0.06 | 0.09 | 0.01 | 0.04 |
| Weighted average number of shares of common stock used in computing basic and diluted net loss per share | 18,646,942 | 16,174,658 | 18,701,418 | 16,444,399 |
-F-3-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.